Celyad Oncology SA 0QFK.L Stock
Celyad Oncology SA Price Chart
Celyad Oncology SA 0QFK.L Financial and Trading Overview
| Celyad Oncology SA stock price | 0.37 EUR |
| Previous Close | 0.54 EUR |
| Open | 0 EUR |
| Bid | 0 EUR x 0 |
| Ask | 0 EUR x 0 |
| Day's Range | 0 - 0 EUR |
| 52 Week Range | 0 - 2.19 EUR |
| Volume | 7.6K EUR |
| Avg. Volume | 1.62K EUR |
| Market Cap | 61.1K EUR |
| Beta (5Y Monthly) | 1.721455 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.442 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0QFK.L Valuation Measures
| Enterprise Value | -802646 EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.6387434 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.041 |
Trading Information
Celyad Oncology SA Stock Price History
| Beta (5Y Monthly) | 1.721455 |
| 52-Week Change | -74.23% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.19 EUR |
| 52 Week Low | 0 EUR |
| 50-Day Moving Average | 1.08 EUR |
| 200-Day Moving Average | 1.08 EUR |
0QFK.L Share Statistics
| Avg. Volume (3 month) | 1.62K EUR |
| Avg. Daily Volume (10-Days) | 2.59K EUR |
| Shares Outstanding | 11.94M |
| Float | 13.58M |
| Short Ratio | N/A |
| % Held by Insiders | 8.83% |
| % Held by Institutions | 20.94% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -25.41% |
| Return on Equity (ttm) | -170.71% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -19551000 EUR |
| Net Income Avi to Common (ttm) | -40935000 EUR |
| Diluted EPS (ttm) | -1.442 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 12.45M EUR |
| Total Cash Per Share (mrq) | 0.55 EUR |
| Total Debt (mrq) | 255K EUR |
| Total Debt/Equity (mrq) | 5.91 EUR |
| Current Ratio (mrq) | 1.422 |
| Book Value Per Share (mrq) | 0.191 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -28010000 EUR |
| Levered Free Cash Flow (ttm) | -10587875 EUR |
Profile of Celyad Oncology SA
| Country | United Kingdom |
| State | N/A |
| City | Mont-Saint-Guibert |
| Address | Axis Business Park |
| ZIP | 1435 |
| Phone | 32 1 039 41 00 |
| Website | https://www.celyad.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 35 |
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Q&A For Celyad Oncology SA Stock
What is a current 0QFK.L stock price?
Celyad Oncology SA 0QFK.L stock price today per share is 0.37 EUR.
How to purchase Celyad Oncology SA stock?
You can buy 0QFK.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Celyad Oncology SA?
The stock symbol or ticker of Celyad Oncology SA is 0QFK.L.
How many shares does Celyad Oncology SA have in circulation?
The max supply of Celyad Oncology SA shares is 121.22K.
What is Celyad Oncology SA Price to Earnings Ratio (PE Ratio)?
Celyad Oncology SA PE Ratio is now.
What was Celyad Oncology SA earnings per share over the trailing 12 months (TTM)?
Celyad Oncology SA EPS is -1.442 EUR over the trailing 12 months.